Drug Profile
VAX 125
Alternative Names: Flagellin.HuHA; Hemagglutinin (HA)-based seasonal influenza vaccine - VaxInnate; STF2.HA1 (SI) - VaxInnate; VAX125Latest Information Update: 30 Jun 2020
Price :
$50
*
At a glance
- Originator VaxInnate
- Class Influenza A vaccines; Recombinant fusion proteins
- Mechanism of Action Immunostimulants; Toll-like receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Influenza A virus infections
Most Recent Events
- 18 Jun 2020 CJ HealthCare is now called HK inno.N
- 27 Aug 2015 No recent reports on development identified - Phase-II for Influenza-A virus infections (In the elderly) in USA (IM)
- 19 Dec 2011 VaxInnate's recombinant seasonal and pandemic influenza vaccines licensed to CJ CheilJedang Corporation exclusively in South Korea, and non-exclusively in certain South-East Asia countries, excluding China